 Joanna Poczobutt
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages, Alveolar | 3 | 2021 | 389 | 1.120 |
Why?
| | Tumor Microenvironment | 7 | 2020 | 634 | 1.090 |
Why?
| | Lung Neoplasms | 9 | 2020 | 2339 | 0.930 |
Why?
| | Niemann-Pick Disease, Type A | 1 | 2021 | 4 | 0.740 |
Why?
| | Niemann-Pick Disease, Type B | 1 | 2021 | 4 | 0.740 |
Why?
| | Lysophospholipase | 1 | 2021 | 10 | 0.730 |
Why?
| | Sphingomyelin Phosphodiesterase | 1 | 2021 | 22 | 0.730 |
Why?
| | Carcinoma, Lewis Lung | 2 | 2019 | 13 | 0.660 |
Why?
| | Glycoproteins | 1 | 2021 | 338 | 0.630 |
Why?
| | Macrophages | 3 | 2021 | 1478 | 0.540 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2015 | 42 | 0.500 |
Why?
| | Pneumonia | 1 | 2021 | 613 | 0.480 |
Why?
| | Adenocarcinoma | 3 | 2017 | 895 | 0.460 |
Why?
| | Leukotrienes | 1 | 2013 | 37 | 0.430 |
Why?
| | Eicosanoids | 1 | 2013 | 57 | 0.430 |
Why?
| | Monocytes | 1 | 2016 | 551 | 0.410 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2019 | 629 | 0.380 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2011 | 328 | 0.370 |
Why?
| | Disease Models, Animal | 8 | 2022 | 4049 | 0.340 |
Why?
| | Breast | 1 | 2010 | 153 | 0.320 |
Why?
| | Mice | 15 | 2022 | 16861 | 0.300 |
Why?
| | T-Lymphocytes | 2 | 2017 | 1928 | 0.300 |
Why?
| | Mice, Knockout | 5 | 2021 | 2856 | 0.290 |
Why?
| | Epithelial Cells | 2 | 2011 | 1064 | 0.280 |
Why?
| | Macrophage Activation | 2 | 2021 | 188 | 0.270 |
Why?
| | Group IV Phospholipases A2 | 2 | 2017 | 47 | 0.250 |
Why?
| | Mice, Inbred C57BL | 9 | 2022 | 5408 | 0.240 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 257 | 0.240 |
Why?
| | PPAR gamma | 2 | 2019 | 183 | 0.230 |
Why?
| | Myeloid Cells | 2 | 2019 | 143 | 0.230 |
Why?
| | Animals | 16 | 2022 | 35219 | 0.220 |
Why?
| | Cell Line, Tumor | 6 | 2019 | 3211 | 0.210 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2016 | 443 | 0.200 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 232 | 0.190 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2021 | 11 | 0.180 |
Why?
| | Th1-Th2 Balance | 1 | 2021 | 8 | 0.180 |
Why?
| | Chitinases | 1 | 2021 | 9 | 0.180 |
Why?
| | CD11 Antigens | 1 | 2021 | 29 | 0.180 |
Why?
| | CD11b Antigen | 1 | 2021 | 60 | 0.180 |
Why?
| | Cell Size | 1 | 2021 | 89 | 0.180 |
Why?
| | Lectins | 1 | 2021 | 46 | 0.180 |
Why?
| | Cigarette Smoking | 1 | 2022 | 91 | 0.180 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2019 | 157 | 0.170 |
Why?
| | Disease Progression | 4 | 2019 | 2622 | 0.170 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 81 | 0.170 |
Why?
| | Pulmonary Emphysema | 1 | 2022 | 275 | 0.160 |
Why?
| | Phagocytosis | 1 | 2021 | 361 | 0.160 |
Why?
| | Lung | 3 | 2022 | 3916 | 0.160 |
Why?
| | Culture Media, Conditioned | 3 | 2021 | 110 | 0.160 |
Why?
| | Eosinophils | 1 | 2021 | 323 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 270 | 0.150 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 362 | 0.150 |
Why?
| | Breast Neoplasms | 1 | 2010 | 2142 | 0.150 |
Why?
| | Trans-Activators | 1 | 2020 | 387 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 202 | 0.140 |
Why?
| | Receptors, Complement | 1 | 2017 | 122 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 181 | 0.140 |
Why?
| | Ureteral Obstruction | 1 | 2017 | 62 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 428 | 0.130 |
Why?
| | Transcriptome | 2 | 2021 | 885 | 0.130 |
Why?
| | Adventitia | 1 | 2016 | 43 | 0.130 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2016 | 67 | 0.130 |
Why?
| | Immunocompetence | 1 | 2016 | 44 | 0.130 |
Why?
| | Gene Expression | 1 | 2021 | 1469 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2019 | 769 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2016 | 259 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2019 | 2388 | 0.120 |
Why?
| | Neutrophils | 1 | 2021 | 1202 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 194 | 0.120 |
Why?
| | Immunohistochemistry | 2 | 2019 | 1696 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2020 | 663 | 0.120 |
Why?
| | Chemokines | 1 | 2016 | 225 | 0.120 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 331 | 0.120 |
Why?
| | Complement Activation | 1 | 2017 | 376 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 981 | 0.110 |
Why?
| | Carcinogenesis | 1 | 2016 | 213 | 0.110 |
Why?
| | Neointima | 1 | 2014 | 15 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 481 | 0.110 |
Why?
| | Kidney Diseases | 1 | 2017 | 383 | 0.110 |
Why?
| | Paracrine Communication | 1 | 2014 | 61 | 0.110 |
Why?
| | Vascular System Injuries | 1 | 2014 | 73 | 0.100 |
Why?
| | Immunotherapy | 1 | 2017 | 592 | 0.100 |
Why?
| | Metabolic Networks and Pathways | 1 | 2013 | 178 | 0.100 |
Why?
| | Lipid Metabolism | 1 | 2016 | 497 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 813 | 0.100 |
Why?
| | Mice, Transgenic | 4 | 2022 | 2111 | 0.100 |
Why?
| | Stem Cells | 1 | 2016 | 577 | 0.100 |
Why?
| | Gene Deletion | 1 | 2013 | 378 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2015 | 1156 | 0.090 |
Why?
| | Extracellular Matrix | 1 | 2016 | 503 | 0.090 |
Why?
| | Cells, Cultured | 3 | 2021 | 4072 | 0.090 |
Why?
| | Coculture Techniques | 3 | 2021 | 226 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1056 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2014 | 457 | 0.090 |
Why?
| | Mammary Glands, Human | 1 | 2011 | 64 | 0.090 |
Why?
| | Cytoplasm | 1 | 2011 | 263 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1049 | 0.090 |
Why?
| | Colony-Forming Units Assay | 1 | 2010 | 90 | 0.090 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 385 | 0.080 |
Why?
| | Humans | 12 | 2022 | 129212 | 0.080 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2009 | 29 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 1891 | 0.080 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2009 | 76 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1705 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2011 | 643 | 0.080 |
Why?
| | Mice, Nude | 1 | 2010 | 683 | 0.080 |
Why?
| | Cell Communication | 1 | 2010 | 300 | 0.080 |
Why?
| | Metabolomics | 1 | 2013 | 652 | 0.070 |
Why?
| | Signal Transduction | 3 | 2019 | 4913 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 832 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 1 | 2011 | 637 | 0.070 |
Why?
| | Blotting, Western | 1 | 2010 | 1205 | 0.070 |
Why?
| | Carcinoma | 1 | 2009 | 216 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 3791 | 0.070 |
Why?
| | Peptide Fragments | 1 | 2011 | 690 | 0.070 |
Why?
| | MAP Kinase Signaling System | 1 | 2009 | 311 | 0.070 |
Why?
| | Male | 6 | 2021 | 63491 | 0.070 |
Why?
| | Female | 5 | 2021 | 68600 | 0.070 |
Why?
| | Cytokines | 2 | 2014 | 2011 | 0.060 |
Why?
| | Phenotype | 2 | 2014 | 3074 | 0.060 |
Why?
| | Thyroid Neoplasms | 1 | 2009 | 309 | 0.060 |
Why?
| | Mutation | 2 | 2019 | 3715 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1443 | 0.050 |
Why?
| | Transcription Factors | 1 | 2011 | 1649 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1354 | 0.050 |
Why?
| | Inflammation | 1 | 2013 | 2723 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 84 | 0.050 |
Why?
| | Leukocytes | 1 | 2022 | 303 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 270 | 0.040 |
Why?
| | Cellular Reprogramming | 1 | 2021 | 95 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 26 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2019 | 56 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 187 | 0.040 |
Why?
| | Cattle | 1 | 2021 | 977 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 259 | 0.040 |
Why?
| | Metabolome | 1 | 2021 | 338 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 33 | 0.040 |
Why?
| | Complement C3d | 1 | 2017 | 65 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 203 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 275 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 389 | 0.030 |
Why?
| | Fibroblasts | 1 | 2021 | 944 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 201 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 520 | 0.030 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 17 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 274 | 0.030 |
Why?
| | Femoral Artery | 1 | 2014 | 173 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1181 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 447 | 0.020 |
Why?
| | Nuclear Export Signals | 1 | 2011 | 4 | 0.020 |
Why?
| | Nuclear Localization Signals | 1 | 2011 | 15 | 0.020 |
Why?
| | Transfection | 1 | 2014 | 908 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2011 | 63 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2011 | 53 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2011 | 213 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 376 | 0.020 |
Why?
| | Thiazolidinediones | 1 | 2011 | 137 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1364 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 361 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 282 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 425 | 0.020 |
Why?
| | Butadienes | 1 | 2009 | 36 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2016 | 1899 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 837 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2009 | 195 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 207 | 0.020 |
Why?
| | Nitriles | 1 | 2009 | 172 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2011 | 2056 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2830 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 826 | 0.020 |
Why?
| | Cell Line | 1 | 2011 | 2777 | 0.020 |
Why?
| | Rats | 1 | 2014 | 5462 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 6384 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 6549 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2011 | 1218 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 3968 | 0.010 |
Why?
|
|
Poczobutt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|